EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of Anticancer Targets in Ovarian Cancer Using Genomic Drug Sensitivity Data

Yebin Son, Jae Yong Ryu

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yebin Son und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Duksung Women's University, 33 Samyang-Ro 144-Gil, Dobong-gu, Seoul 01369, Republic of Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Research Foundation of Korea (NRF) grant, National Research Foundation of Korea (NRF) grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARP inhibitors exploit synthetic lethality in BRCA1/2-mutated ovarian cancers but are limited by emerging therapeutic resistance. Therefore, novel biomarkers predicting PARP inhibitor response are urgently needed. In this study, we performed integrative analysis using drug sensitivity, patient survival, gene dependency, and expression data to identify biomarkers associated with PARP inhibitor response in ovarian cancer. Mutations in BRCA1, MLL2, NF1, and SMARCA4 were associated with increased sensitivity to PARP inhibitors, suggesting potential synthetic lethality with PARP1. In contrast, SMAD4 mutations were linked to PARP inhibitor resistance, and low SMAD4 expression was associated with poor overall survival in patients with ovarian cancer. Further gene dependency score (GDS)-based screening revealed 51 candidate genes potentially involved in SMAD4-mediated resistance. Functional enrichment revealed associations with stress response, tumor-associated signaling pathways, and additional processes. Subsequent correlation and survival analyses nominated ACACA, PRPF4B, and TUBD1 as potential therapeutic targets. Notably, low ACACA expression in patients with low SMAD4 expression was associated with improved survival, indicating its relevance in overcoming PARP inhibitor resistance. This study contributes to predicting clinical outcomes in ovarian cancer and developing personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsDrug Resistance, NeoplasmPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsHumansFemaleSmad4 ProteinBiomarkers, TumorMutationGene Expression Regulation, NeoplasticGenomics

Stichwörter der Autor:innen

PARP inhibitorsbiomarkerdrug sensitivitygene dependency scoreovarian cancertarget discovery

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsSmad4 ProteinBiomarkers, TumorSMAD4 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biotechnology, Duksung Women's University, 33 Samyang-Ro 144-Gil, Dobong-gu, Seoul 01369, Republic of Korea.
  • Department of Biomedical Systems Engineering, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul 06978, Republic of Korea.

Förderung

  • The National Research Foundation of Korea (NRF) grant
  • National Research Foundation of Korea (NRF) grant

Zitieren

APA

Son, Y., & Ryu, J. Y. (2025). Identification of Anticancer Targets in Ovarian Cancer Using Genomic Drug Sensitivity Data. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199530

Vancouver

Son Y, Ryu JY. Identification of Anticancer Targets in Ovarian Cancer Using Genomic Drug Sensitivity Data. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199530

BibTeX
@article{Son2025,
  author = {Son, Yebin and Ryu, Jae Yong},
  title = {Identification of Anticancer Targets in Ovarian Cancer Using Genomic Drug Sensitivity Data},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199530}
}
Kostenlos starten →